Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
NYS Entity Status
NYS Filing Date
MAY 01, 2013
NYS DOS ID#
500 WEST 43RD STREET, APT. 31F
NEW YORK, NEW YORK, 10036
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2013 - BETH ZISMAN & COMPANY LLC
Around the Web
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
- Women of Sex Tech, Unite
By ANNA NORTH - Friday Aug 18, 2017
New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]
- How Beth Mowins blocks out negativity chasing NFL dream
By Justin Terranova - Thursday Sep 21, 2017
Beth Mowins chats with The Post’s Justin Terranova about the responsibility of being the second woman to call an NFL game. Mowins makes her NFL on CBS debut Sunday with play-by-play of the Browns-Colts game after she called Broncos-Chargers game on ESPN in Week 1. Q: How did this come about? A: I’ve always wanted...
- Coffee recalled for containing Viagra-like ingredient
By Fox News - Thursday Jul 20, 2017
A company based in Texas has recalled a coffee product after a substance found in a drug used to treat erectile dysfunction was found in the product, the Food and Drug Administration (FDA) confirmed. Bestherbs Coffee LLC has recalled all of its “New of Kopi Jantan Tradisional Herbs Coffee” after the FDA said it found...
- IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
By Ben Fidler - Thursday Aug 3, 2017
Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]